PT  - JOURNAL ARTICLE
AU  - Keino Hutchinson
AU  - Dina Buitrago Silva
AU  - Joshua Bohlke
AU  - Chase Clausen
AU  - Allen A. Thomas
AU  - Massimiliano Bonomi
AU  - Avner Schlessinger
TI  - Describing Inhibitor Specificity for the Amino Acid Transporter LAT1 from Metainference Simulations
AID  - 10.1101/2022.05.03.490502
DP  - 2022 Jan 01
TA  - bioRxiv
PG  - 2022.05.03.490502
4099  - http://biorxiv.org/content/early/2022/05/03/2022.05.03.490502.short
4100  - http://biorxiv.org/content/early/2022/05/03/2022.05.03.490502.full
AB  - The human L-type amino acid transporter 1 (LAT1; SLC7A5) is a membrane transporter of amino acids, thyroid hormones, and drugs such as the Parkinson’s disease drug L-Dopa. LAT1 is found in the blood-brain-barrier (BBB), testis, bone marrow, and placenta, and its dysregulation has been associated with various neurological diseases such as autism and epilepsy as well as cancer. In this study, we combine metainference molecular dynamics (MD) simulations, molecular docking, and experimental testing, to characterize LAT1-inhibitor interactions. We first conducted a series of molecular docking experiments to identify the most relevant interactions between LAT1’s substrate binding site and ligan ds, including both inhibitors and substrates. We then performed metainference MD simulations using cryo-EM structures in different conformations of LAT1 with the electron density map as a spatial restraint, to explore the inherent heterogeneity in the structures. We analyzed the LAT1 substrate binding site to map important LAT1-ligand interactions as well as newly described druggable pockets. Finally, this analysis guided the discovery of previously unknown LAT1 ligands using virtual screening and cellular uptake experiments. Our results improve our understanding of LAT1-inhibitor recognition, providing a framework for rational design of future lead compounds targeting this key drug target.Statement of Significance LAT1 is a membrane transporter of amino acids, thyroid hormones, and therapeutic drugs, that is primarily found in the BBB and placenta, as well as in tumor cells of several cancer types. We combine metainference MD simulations, molecular docking, and experimental testing, to characterize LAT1-inhibitor interactions. Our computational analysis predicts S66, G67, F252, G255, Y259, W405 are critical residues for inhibitor binding and druggable sub-pockets in the outward-occluded conformation that are ideal for LAT1 inhibitor discovery. Using virtual screening and functional testing, we discovered multiple LAT1 inhibitors with diverse scaffolds and binding modes. Our results improve our understanding of LAT1’s structure and function, providing a framework for development of future therapeutics targeting LAT1 and other SLC transporters.Competing Interest StatementThe authors have declared no competing interest.